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In vivo, theta (4e7 Hz) and gamma (30e80 Hz) neuronal network oscillations are known to coexist and
display phase-amplitude coupling (PAC). However, in vitro, these oscillations have for many years been
studied in isolation. Using an improved brain slice preparation technique we have, using co-application
of carbachol (10 mM) and kainic acid (150 nM), elicited simultaneous theta (6.6 ± 0.1 Hz) and gamma
(36.6 ± 0.4 Hz) oscillations in rodent primary motor cortex (M1). Each oscillation showed greatest power
in layer V. Using a variety of time series analyses we detected signiﬁcant cross-frequency coupling in 74%
of slice preparations.
Differences were observed in the pharmacological proﬁle of each oscillation. Thus, gamma oscillations
were reduced by the GABAA receptor antagonists, gabazine (250 nM and 2 mM), and picrotoxin (50 mM)
and augmented by AMPA receptor antagonism with SYM2206 (20 mM). In contrast, theta oscillatory
power was increased by gabazine, picrotoxin and SYM2206. GABAB receptor blockade with CGP55845
(5 mM) increased both theta and gamma power, and similar effects were seen with diazepam, zolpidem,
MK801 and a series of metabotropic glutamate receptor antagonists. Oscillatory activity at both fre-
quencies was reduced by the gap junction blocker carbenoxolone (200 mM) and by atropine (5 mM).
These data show theta and gamma oscillations in layer V of rat M1 in vitro are cross-frequency coupled,
and are mechanistically distinct. The development of an in vitro model of phase-amplitude coupled
oscillations will facilitate further mechanistic investigation of the generation and modulation of coupled
activity in mammalian cortex.
© 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Gamma oscillations (30e80 Hz) play a role in attentive states
such as sensory perception (Engel and Singer, 2001; Gray et al.,
1989; Gray, 1994; Singer and Gray, 1995), memory processing
(Chrobak and Buzsaki, 1998; Lisman and Idiart, 1995) and move-
ment execution (Brown et al., 1998; Cheyne et al., 2008;CCh, carbachol; EPSC, excit-
tic potential; IPSP, inhibitory
potential; M1, primary motor
, Phase-amplitude coupling.
oodhall).
Ltd. This is an open access article uMuthukumaraswamy, 2010; Pfurtscheller et al., 2003). Exten-
sively studied both in vivo and in vitro, gamma oscillations appear to
be an emergent property of reciprocally connected inhibitory
interneuronal network and pyramidal cells. Whilst excitatory post-
synaptic potentials, shunting inhibition and gap junctions play a
role in the generation of synchronous activity, the main determi-
nant of the oscillatory frequency is the time constant of decay of
interneuron-derived GABA currents (Fisahn et al., 1998; Traub et al.,
1996, 2000; Wang and Buzsaki, 1996; Whittington et al., 1995).
Theta oscillations (4e7 Hz) are associated with hippocampal
and limbic regions involved in exploration, spatial navigation
(Cacucci et al., 2004; O'Keefe and Recce, 1993) and spatial and
working memory (Buzsaki and Moser, 2013; Cashdollar et al.,
2009). During exploration, network oscillations at gamma andnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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theta being temporally nested with gamma rhythm (Fisahn et al.,
1998; Sirota et al., 2008). Due to conduction delays, low fre-
quency oscillations are able to prefentially synchronise networks
over long distances while faster oscillations are thought to syn-
chronise activity in more local networks. Thus, the amplitude of the
gamma frequency oscillation is enhanced in phase with the theta
cycle due to neuron recruitment. This phenomenon, known as
cross-frequency coupling (CFC; Canolty et al., 2006), aids inter-
neuronal network communication and processing such that com-
munications arriving out of phase may be ignored while
information in phase may be treated preferentially. In this way,
theta may serve to act as a global temporal coordinator of local
network activity (Sirota et al., 2008), and theta-gamma coupling
has been shown to be essential for structuring of motor-related
activity in rodent M1 (Igarashi et al., 2013).
An understanding of the fundamental mechanisms involved in
the generation of neuronal network theta and gamma oscillations
has arisen from in vitro studies using stimulus-based and/or phar-
macological approaches to induce activity, which may then be
characterised using a combination of electrophysiology and
neuropharmacology. Thus, transient (lasting milliseconds to sec-
onds) gamma oscillations have been evoked by tetanic electrical
stimulation (Traub et al., 1996; Whittington et al., 1997) whilst
persistent (lasting hours) gamma oscillations have been generated
by application of kainic acid (KA) and/or carbachol (CCh) (Buhl
et al., 1998; Cunningham et al., 2003; Dickson et al., 2000; Fisahn
et al., 1998) or group 1 metabotropic glutamate receptor (mGluR)
activation (Fisahn et al., 1998; Palhalmi et al., 2004; Whittington
et al., 1995). Furthermore, theta rhythms can be generated by the
addition of GABAA receptor antagonists along with CCh (Konopacki
and Golebiewski, 1993; Lukatch and MacIver, 1997; MacIver et al.,
1986) or AMPA receptor antagonists with mGluR agonists (Cobb
et al., 2000; Gillies et al., 2002). In addition, rhythm generation is
also enhanced by electrical coupling through gap junctions (Bocian
et al., 2011; Kopell and Ermentrout, 2004; Szabadics et al., 2001;
Tamas et al., 2000) which are prevalent between interneurons
(Beierlein et al., 2000; Deans et al., 2001; Galarreta and Hestrin,
1999).
Previous studies inM1 in vitro have shown that co-application of
KA and CCh elicits beta oscillations (Lacey et al., 2014; Yamawaki
et al., 2008) while electrical stimulation at different frequencies
evoked theta, beta and gamma activity revealing the ability for M1
to promote multiple rhythms of different frequencies (Yamawaki
et al., 2008). In this study, using an improved brain slice prepara-
tion based on a protocol utilising a number of neuroprotective
agents, we have been able to generate pharmacologically-induced
persistent theta and gamma oscillations in M1 that demonstrates
CFC. Furthermore, pharmacological investigations reveal that theta
activity is generated andmodulated by distinct receptor types, with
contributions from both intrinsic and synaptic mechanisms.
2. Materials and methods
2.1. In vitro slice preparation
Sagittal brain slices (450 mm thick) containing M1 were pre-
pared from male Wistar rats (20e30 days of age, 50e150 g). All
animal procedures were performed in accordance with the Aston
University policy and in accordance with the Animals (Scientiﬁc
Procedures) Act UK 1986 and European Communities Directive
2010/63/EU. Animals were ﬁrst anaesthetised using isoﬂurane (2%
in O2) until no heartbeat was detected and then transcardially
perfused with ice-cold sucrose-based artiﬁcial cerebral spinal ﬂuid
(aCSF) containing (in mM): 180 sucrose, KCl 2.5, MgSO4 10,NaH2PO4 1.25, NaHCO3 25 Glucose 10, CaCl2 0.5, ascorbic acid 1, N-
acetyl cysteine 2, taurine 1, Ethyl pyruvate 20 and saturated with
95% O2 and 5% CO2 at pH 7.3, 300e310 mOsm. Indomethacin
(45 mM), aminoguanidine (200 mM) and uric acid (400 mM) were
added to improve slice viability (Grifﬁths et al., 1993; Pakhotin
et al., 1997; Proctor, 2008). The brain was quickly removed and
placed into the same sucrose-based aCSF. Using a HM-650V
Microslicer (Microm GMBH, Germany) sagittal slices were cut at
room temperature. Slices were then transferred to an interface
holding chamber at room temperature containing oxygenated
standard aCSF containing (in mM): NaCl 126, KCl 3, MgSO4 1.6,
NaH2PO4 1.25, NaHCO3 26, glucose 10, CaCl2 2 with an osmolarity
between 300 and 310 mOsm, where they were left for at least 1 h.
2.2. Extracellular recordings
Slices were transferred to an interface recording chamber (Sci-
entiﬁc System Design Inc., Canada) at 32e34 C and continually
perfused at 1e2 ml/min with standard aCSF. Local ﬁeld potential
(LFP) recordings were made using borosilicate glass microelec-
trodes pulled on a Flaming-Brown micropipette puller (P-2000;
Sutter Instrument Co., USA) ﬁlled with standard aCSF (resistance of
1e3 MU). For cross-correlation recordings, electrodes were placed
in a single slice (in layers II/III, Va and Vb), in a single vertical col-
umn and recorded for at least 20 min. Signals were ampliﬁed 1000-
fold using an EXT10-2F ampliﬁer and an LHBF-48X ﬁlter (NPI
Electronics GMBH, Germany), high- and low-pass ﬁltered at 0.5 Hz
and 700 Hz respectively. Low amplitude 50 Hz signal interference
was removed using a HumBug (Quest Scientiﬁc, North Vancouver,
Canada). Signals were digitized and recorded at 10 kHz using a CED
micro-1401 mkII digitizer and Spike2 software (Cambridge Elec-
tronic Design, UK) and saved to disk.
2.3. Drug application
Oscillatory activity was induced through bath application of KA
(150 nM) and CCh (10 mM) and left to stabilise for at least 60 min
prior to recording. Drugs were bath applied in known concentra-
tions having been previously prepared in stock solutions of
1e50 mM and stored at 20 C prior to application. The drugs used
were carbamoylcholine chloride (carbachol), carbenoxolone, diaz-
epam, zolpidem, atropine (Sigma Ltd., Gillingham, UK), kainic acid,
CPCCOEt, gabazine, MPEP hydrochloride (Abcam, Cambridge, UK)
and CGP58845, LY341495, MK-801, picrotoxin and SYM2206 (Tocris
Bioscience, Bristol, UK). All drugs were left for at least 40min before
data was sampled or next dose was applied, with the exception of
carbenoxolone which was applied for at least 90 min.
2.4. Data analysis
Data were analysed off-line using Spike2 (CED, UK). Raw data
presented were ﬁltered using IIR digital ﬁltering by Bessel band
pass between 3 and 10 Hz for theta oscillations and 30e45 Hz for
gamma oscillations and were forward and reverse ﬁltered using a
custom Matlab script in order to preserve phase information. Some
data (presented in Fig.1Ai) were ﬁltered using IIR digital ﬁltering by
Bessel low-pass at 60 Hz. Time-frequency proﬁles were generated
using aMorlet-wavelet time-frequency analysis over the 0.5e50 Hz
range in frequency bins of 0.5 Hz. Cross- and auto-correlation
graphs were generated in Spike2 and referenced to the electrode
in LVa. These were presented over 0.2 s for theta oscillations and
0.02 s for gamma oscillations. Results were pooled from 6 re-
cordings to provide a mean result ± SEM. Changes to power values
were derived from power spectra generated with Fourier analysis
on digitized data of 40 s epochs of recorded activity from control
Fig. 1. Dual application of CCh and KA elicits simultaneous theta and gamma oscillations in layer V of M1.
(Ai) Data recorded in layer V of M1 following application of CCh (10 mM) and KA (150 nM) and low-pass ﬁltered at 60 Hz (ii) a time-frequency spectrogram of data in Ai (Bi)
Emergent theta activity ﬁltered at 3e10 Hz and (ii) gamma activity ﬁltered at 30e45 Hz following application of CCh and KA (C) Representative power spectra demonstrating
emergence of theta and gamma oscillatory activity following application of CCh (dashed line) and subsequent addition of KA (dotted line). (D) Bar graphs showing peak oscillatory
power of theta (grey bars) and gamma (red bars) oscillations normalised to control. ***p < 0.001.
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are represented as mean peak power values normalised to
control ± SEM. Statistical analyses performed were Wilcoxon
matched-pairs signed rank test for all data except diazepam,
gabazine, LY341495 and zolpidem where the Kruskal-Wallis test
followed by Dunn's multiple comparisons test was performed to
account for the consecutive concentrations of the drug tested. No
signiﬁcance is signiﬁed by “ns”, whilst p < 0.05 is denoted by *,
p < 0.01 by ** and p < 0.001 by ***. Signiﬁcant changes in power andfrequency are given in a summary table (Table 1) with changes
denoted by arrows (up represents increased frequency or power
and down shows decrease. Number of arrows corresponds to sig-
niﬁcance at 1, 2 or 3*).2.5. Modulation index (MI) and peak-triggered average analysis
Modulation index analyses were performed in Matlab (R2015b)
by MathWorks. Analyses presented in Fig. 2 were performed on
Table 1
Summary of theta-gamma frequency and power changes in response to various
ligands.
Drug N (Slice) Theta Gamma
Frequency Power Frequency Power
GABAergic receptors
Gabazine 250 nM 7 e [ e YYY
2 mM 7 YY [[[ YY YY
Picrotoxin 50 mM 8 e [[ YY YY
Diazepam 30 mM 8 e e e e
100 mM 8 e [ Y [
Zolpidem 10 Nm 14 e e e [
30 nM 14 e e Y [[[
100 nM 8 e
CGP55845 5 mM 17 [[ [[ [[ [[[
Ionotropic glutamate receptors
SYM 2206 20 mM 20 YYY [[[ Y YYY
MK-801 20 mM 12 e [[[ YYY [[[
Metabotropic glutamate receptors
CPCCOEt 20 mM 7 e [ Y [
MTEP 100 mM 8 e [[ e [[
Cholinergic receptors
Atropine 5 mM 7 e [ e [
Gap junctions
Carbenoxolone 200 mM 13 YY YYY e YYY
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ﬁgures and analyses. Measurement of Phase-amplitude coupling
(PAC) to determine the modulation index of theta and gamma os-
cillations were performed using purpose built scripts previouslyFig. 2. Topography of theta-gamma oscillations across layers of M1.
Frequency (i) and power (ii) of (A) theta and (B) gamma oscillations from the superﬁcial (lay
time between layers.described in Tort et al. (2010). Modulation index is presented as the
mean ± SEM. In order to ensure robustness a high frequency peak-
triggered average of the LFP was also constructed using a Matlab
script supplied by B Polletta, based on the work of Lopez-Azcarate
et al. (2013). We set a threshold of MI > 0.0001 as evidence of
coupling, and coupling was found in around 75% of slices tested.
3. Results
Recording in layer V of M1, application of CCh and KA generated
simultaneous rhythms at theta frequency (6.6 ± 0.1 Hz, n ¼ 169)
and gamma frequency (36.6 ± 0.4 Hz, n ¼ 169; Fig. 1Ai and Aii).
Application of CCh (10 mM) resulted in a signiﬁcant increase in
neuronal activity at theta frequency (control mean peak power
2.50 ± 0.61 mV2 versus 10.14 ± 2.43 mV2 in CCh; n ¼ 11, p < 0.05;
Fig. 1BeD) and gamma frequency (control mean peak power
0.54 ± 0.13 mV2 versus 1.89 ± 0.43 mV2 in CCh; n ¼ 11, p < 0.05;
Fig. 1BeD). Subsequent addition of KA (150 nM) signiﬁcantly
increased the neuronal activity resulting in continuous oscillatory
activity in the theta (mean peak power 23.48 ± 5.16 mV2, n ¼ 11,
p < 0.001 compared to control; Fig. 1BeD) and gamma (22.17 ± 5.71
mV2, n ¼ 11, p < 0.001 compared to control; Fig. 1BeD) frequency
ranges. Hence, co-application of both KA and CCh was required to
reliably produce theta and gamma oscillations and was used for all
further experiments. Interestingly, and as shown in the represen-
tative power spectrum in Fig. 1C, following addition of both KA and
CCh we sometimes noted a peak in the low beta band (13e21 Hz)
and a shift in peak theta frequency towards higher values. The latterer II/III) to the deep (layer Vb) layers and (iii) cross-correlations demonstrating the lag
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application of KA that was in addition to the existing CCh-induced
theta oscillation.
Previous work in our laboratory (Yamawaki et al., 2008) showed
that the amplitude of beta oscillatory activity was greatest in deep
layers of M1 and we next investigated the power of theta and
gamma activity across cortical layers. On moving the recording
electrode stepwise down from the pial surface of M1 towards the
striatum, we found the power of both theta (Fig. 2Ai-ii) and gamma
activity (Fig. 2Bi-ii) to be greatest in upper layer V. Hence, mean
peak power for theta activity was 22.66 ± 3.03 mV2 in layer II/III,
compared to 61.49 ± 3.01 mV2/Hz in layer Va and 15.85 ± 2.52 mV2 in
layer Vb (n ¼ 6, p < 0.001, ANOVA). Similarly, for gamma activity
mean peak power was 22.27 ± 5.01 mV2 in layer II/III, compared to
51.52 ± 3.59 mV2 in layer Va and 26.21 ± 5.58 mV2 in layer Vb (n ¼ 6,
p < 0.05, ANOVA). However, cross-correlation analysis revealed a
more complex relationship between oscillatory activity in different
layers. As can be seen in Fig. 2Aiii, theta activity in deep M1 (layer
Vb) lagged similar activity in layer Va (average lag 5 ms), as did
activity in superﬁcial M1 (average lag 6 ms). In both cases, corre-
lation coefﬁcients were low (LII/III versus LVa - 0.2164 ± 0.07 and
LVb versus LVa - 0.11 ± 0.04). By contrast, in the case of gamma
oscillations, the waveform in layer Va led layer Vb by an average of
4 ms and lagged superﬁcial layers II/III by 3 ms. Correlation was
much stronger across layers (LII/III versus LVa - 0.38 ± 0.05 LVb
versus LVa - 0.29 ± 0.07). To further explore and understand the
data we next investigated whether any interaction between the
two rhythms could be detected.
The theta-gamma activity present in our in vitro preparationwas
the ﬁrst such simultaneous persistent activity we have observed in
this brain slice preparation, however, cross-frequency coupling has
been shownmany times in vivo. In order to conﬁrm the existence of
cross-frequency coupling in our data, we subjected time series data
to further analyses. Recordings were analysed using themodulation
index, based on the method of Tort et al. (2010), which offers a
means of detecting PAC. The Tort et al. approach calculates how
much an empirical amplitude distribution deviates from an ideal
and produces a numerical output (the modulation index) which is a
measure of the intensity of phase coupling. Although some re-
cordings 14/54 slices (26%) showed no coupling above our
threshold for detection (see methods), in many cases we were able
to determine that theta-gamma oscillations in M1 were coupled
(Fig. 3AeC; modulation index 2.28  104 ± 4.67  105, n ¼ 8).
Similarly, we used the peak of the gamma oscillation waveform to
trigger averaging of the theta oscillatory activity (Lopez-Azcarate
et al., 2013; see methods), and this conﬁrmed that packets of
gamma activity were associated with the peak of the theta wave
(Fig. 3D).
These analyses suggested that theta and gamma activity were
coupled, and in order to provide further evidence of gamma and
theta oscillations arising from separate neuronal networks a
pharmacological dissection of mechanisms underlying the two
oscillations was undertaken.
3.1. GABA receptor modulation of theta-gamma activity
Previous studies have shown that the oscillations in M1 are
dependent on phasic GABAA receptor mediated inhibition
(Yamawaki et al., 2008). Similarly, gamma oscillations have been
shown to be exquisitely sensitive to blockade of GABAA receptor
mediated inhibition by low concentrations of the competitive
GABAA receptor antagonist, gabazine (250 nM). We tested gabazine
at low (250 nM) and high (2 mM) concentration (Roopun et al.,
2006) (Fig. 4A). At 250 nM gabazine signiﬁcantly increased the
power of theta oscillations (147.9± 10.2% of control, n ¼ 7, p < 0.05)while 2 mM gabazine shows an additional effect increasing the
power by 181.0± 11.6% of control, n ¼ 7, p < 0.001 (Fig. 4 Ai, iii, iv).
Both 250 nM and 2 mM gabazine substantially decreased the power
of gamma oscillations (250 nM: 32.3± 4.9% of control, n ¼ 16,
p < 0.001; 2 mM: 27.5± 7.5% of control, n ¼ 7, p < 0.01; Fig. 4Aii, iii,
iv), indicating high sensitivity as previously reported for neocortical
gamma activity. The effect of blocking GABAA receptors was
conﬁrmed using picrotoxin (Fig. 4B), which blocks the GABAA re-
ceptor ionophore. The application of 50 mM picrotoxin caused a
similar decrease in gamma oscillatory power as seenwith gabazine
(28.3± 7.4% of control, n ¼ 8, p < 0.01; Fig. 4Biv) and a signiﬁcant
increase in the power of theta oscillations (239.8± 61.5% of control,
n ¼ 8, p < 0.01; Fig. 4B i-iv).
We have previously shown that beta frequency oscillatory ac-
tivity inM1 is sensitive to ligandswhich bind at the benzodiazepine
site of the GABAA receptor, and we next explored the actions of
benzodiazepine site ligands on theta and gamma activity. The
benzodiazepine site agonist, diazepam, was initially applied at a
concentration of 30 nM but there was no signiﬁcant change in the
power of theta or gamma oscillations at this concentration (theta:
174.0± 43.9% of control, n ¼ 8, ns; gamma: 121.9± 12.9% of control,
n¼ 8, ns; Fig. 5A). However at a concentration of 100 nM diazepam
resulted in a signiﬁcant increase in the power of both theta
(188.8± 26.1% of control, n¼ 8, p < 0.05; Fig. 5Ai, iii, iv) and gamma
oscillations (142.2± 22.3% of control, n¼ 8, p < 0.05; Fig. 5Aii, iii, iv).
Zolpidem is a non-benzodiazepine hypnotic which is speciﬁc for
GABAA receptors containing the a1-subunit at concentrations up to
400 nM (Crestani et al., 2000). When zolpidemwas applied to theta
oscillations there was no signiﬁcant change at 10 and 30 nM con-
centrations (10 nM: 119.1± 6.0% of control, n ¼ 14, ns; 30 nM:
126.4± 10.1% of control, n ¼ 14, ns; Fig. 5Bi, iii, iv). However,
increasing the concentration to 100 nM did result in a signiﬁcant
increase in power (160.7± 16.0% of control, n ¼ 8, p < 0.001). In
contrast, gamma oscillations increased in power upon addition of
zolpidem, at all concentrations tested (10 nM: 148.5± 10.1% of
control, n ¼ 14, p < 0.05; 30 nM: 87.1± 14.4%, n ¼ 14, p < 0.001:
100 nM: 276.3± 28.0% of control, n ¼ 8, p < 0.001; Fig. 5Bii, iii, iv).
Finally, we investigated the involvement of GABAB receptor
mediated inhibition in theta and gamma oscillations using the
GABAB receptor antagonist, CGP55845, at 5 mM. Unlike the differing
effects of the GABAA receptor antagonists, both theta and gamma
oscillations showed signiﬁcant increases in power in 5 mM
CGP55845. Theta oscillations increased in power to 131.8± 10.6% of
control (n ¼ 17, p < 0.01, Fig. 6Ai and B and C) and gamma oscil-
lations increased in power to 149.4± 10.9% of control (n ¼ 17,
p < 0.001, Fig. 6Aii, B and C). Application of CGP55845 also resulted
in signiﬁcant increases in both theta and gamma oscillatory fre-
quencies (theta: to 119.1± 8.7% of control, n ¼ 17, p < 0.01; gamma:
to 133.5± 10.3% of control, n ¼ 17, p < 0.01, data not shown).
3.2. Glutamate receptor modulation of theta-gamma activity
We next determined the role of excitatory glutamatergic
transmission on coupled theta and gamma activity. Firstly, the role
of AMPA receptors in the generation of theta and gamma oscilla-
tions was assessed using the antagonist SYM2206. SYM2206
(20 mM) signiﬁcantly increased the power of the theta oscillations
(333.8± 20.2% of control, n ¼ 20, p < 0.001; Fig. 7Ai, iii, iv). In
contrast, as with the blockade of GABAA receptors, SYM2206
(20 mM) dramatically decreased the power of gamma oscillations
(20.2± 3.2% of control, n ¼ 20, p < 0.001; Fig. 7Aii, iii, iv). It seems
likely that the decrease in gamma activity and the increase in theta
power are entirely separate mechanisms, however, it may be that
SYM2206 merely depresses gamma frequency to the point where it
is slow enough to contribute to an apparent increase in theta
Fig. 3. Phase amplitude cross-frequency coupling and spike-triggered average analysis.
(A) Average phase angle representations of recordings (i) demonstrating theta-gamma PAC and (ii) those not demonstrating theta-gamma PAC. (B) Comodulogram demonstrating
frequency pairs showing PAC (denoted by white arrow) (C) Bar graph demonstrating signiﬁcant difference in modulation index (MI) between recordings showing PAC (þ) and those
not (). (D) Representative spike-triggered average demonstrating gamma frequency oscillation at the peak of theta oscillation. ***, p < 0.001.
N.W. Johnson et al. / Neuropharmacology 119 (2017) 141e156146power. To investigate this, we measured the time course (data not
shown) of the effects of SYM2206 on theta and gamma activity and
it was notable that theta power peaked about 15 min prior to
maximal depression of gamma activity, suggesting mechanistic
independence. To assess the contribution of NMDA receptors we
used the NMDA receptor non-competitive antagonist, ketamine,
(20 mM), which increased theta to 146.6± 9.2% of control, n ¼ 7,
p< 0.05 and gamma: to 201.2± 23.6% of control, n¼ 7, p< 0.05, data
not shown). Since ketamine may have non-NMDA receptor actions,
we conﬁrmed these data using another non-competitive NMDAR
antagonist, MK-801. Application of MK-801 (20 mM) resulted insigniﬁcant increases in both theta and gamma oscillations (theta:
201.3± 22.5% of control, n ¼ 12, p < 0.001; gamma: 254.7± 36.5% of
control, n ¼ 12, p < 0.001; Fig. 7Bi-iv). When we applied compet-
itive NMDAR antagonists, we found gamma, but not theta activity
to be augmented. Hence, when we applied 2-AP5 at 50 mM theta
oscillations showed no signiﬁcant change and gamma power was
enhanced to 166.3± 13.6% of control, (n ¼ 15, p < 0.001, data not
shown) and similar experiments using the high afﬁnity antagonist
CPP (5 mM) again showed no signiﬁcant change to theta power and
increased gamma oscillatory power (179.5± 15.2% of control, n¼ 11,
p < 0.01, data not shown).
Fig. 4. GABAA receptor block increases theta oscillatory power whilst decreasing gamma oscillatory power.
(A) Effects of GABAA receptor antagonist gabazine (250 nM and 2 mM) on (i) theta and (ii) gamma oscillations. (iii) Representative power spectra showing peak power before (solid line) and after 250 nM (dashed line) and 2 mM (dotted
line) gabazine. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. (B) Effect of the GABAA receptor channel blocker picrotoxin (50 mM) on (i) theta and (ii) gamma
oscillations (iii) Representative power spectra demonstrating peak responses before (solid line) and after picrotoxin (dashed line) (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations
normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 5. Differential actions of benzodiazepine site modulation.
(A) Effects of diazepam (30 and 100 nM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra showing peak responses before (solid line) and after application of 30 nM (dashed line) and 100 nM (dotted line)
diazepam. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. (B) Effects of zolpidem (10, 30 and 100 nM) on (i) theta and (ii) gamma oscillations (iii)
Representative power spectra demonstrating peak responses before (solid line) and after application of 10 nM (dashed line), 30 nM (dotted line) and 100 nM (hybrid line) zolpidem. (iv) Bar graphs showing peak oscillatory power of
theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 6. GABAB receptor block increased both theta and gamma oscillatory power.
(A) Effects of GABAB receptor antagonist CGP55845 (CGP, 5 mM) on (i) theta and (ii) gamma oscillations. (B) Representative power spectra showing peak responses before (solid line)
and after application of 5 mM (dashed line) CGP. (C) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control.
*p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
N.W. Johnson et al. / Neuropharmacology 119 (2017) 141e156 149It is well established that activation of mGluRs may induce
oscillatory activity in vitro (Whittington et al., 1995), and we next
investigated the effect of antagonists for each of the group I mGluR
subtypes to assess their involvement in theta and gamma oscilla-
tions in M1. We ﬁrst blocked mGluR1 receptors with the non-
competitive antagonist CPCCOEt. Application of CPCCOEt (20 mM)
resulted in a signiﬁcant increase in the power of both the theta and
gamma oscillations (theta: 184.3± 22.5% of control, n ¼ 7, p < 0.05;
gamma: 216.1± 22.4% of control, n ¼ 7, p < 0.05; Fig. 8A). Whenwe
applied MTEP (20 mM) in order to block mGluR5 receptors, again
this resulted in a signiﬁcant increase in the power of both the theta
and gamma oscillations such that theta power increased to
168.4± 18.5% of control, n ¼ 8, p < 0.01 and gamma to 163.7± 10.8%
of control, n¼ 8, p < 0.01 (Fig. 8B). By contrast, activation of group I
mGluRs with the non-selective agonist, DHPG depressed theta
power and had no signiﬁcant effects on gamma activity (DHPG
theta ¼ 79.9± 4.0% of control, n ¼ 10, p < 0.01 gamma ¼ 89.6± 7.1%
of control, n ¼ 10, ns, data not shown).
3.3. Effects of other ligands on theta-gamma activity
Carbenoxolone has been used extensively to block gap junctions
and has previously been shown to abolish beta oscillations in M1
(Yamawaki et al., 2008). Application of carbenoxolone (200 mM) for
90 min resulted in a signiﬁcant decrease of both theta and gammaoscillatory power (theta: 40.6± 5.1% of control, n ¼ 13, p < 0.001;
gamma: 28.7± 5.7% of control, n ¼ 13, p < 0.001; Fig. 9A). The
involvement of muscarinic acetylcholine receptors (mAChR) in
both theta and gamma oscillations has been shown in vivo and
through the use of CCh to induce oscillations in slices (Konopacki
et al., 1987; Buhl et al., 1998; Fisahn et al., 1998; Lukatch and
MacIver, 1997). Application of atropine (5 mM) completely abol-
ished both theta (24.9± 9.0% of control, n ¼ 7, p < 0.05, Fig. 9B) and
gamma (9.1± 3.3% of control, n ¼ 7, p < 0.05, Fig. 9B) oscillations.
4. Discussion
Using a modiﬁed slice preparation technique to enhance slice
viability we have been able to generate simultaneous theta and
gamma oscillations in sagittal slices of adult rat M1 using a phar-
macological approach. These two rhythms are superﬁcially similar
to ‘mu’ and gamma activity we have reported in M1 in vivo using
magnetoencephalography in human brain (MEG; Ronnqvist et al.,
2013), although it is true to say that ‘natural’ M1 activity rarely
has the power, or the sharply deﬁned peaks seen in the in vitro
brain slice. Presumably this reﬂects the difference between
movement-elicited transient oscillatory activity in vivo and the
strongly driven, persistent activity in vitro. The oscillations we
report here show greatest power in layer V and appear to display
cross-frequency coupling. M1 theta and gamma oscillations are
Fig. 7. AMPA receptor block increases theta power whilst reducing gamma power, whilst NMDA receptor block increased both theta and gamma oscillatory power.
(A) Effect of AMPA receptor antagonist SYM2206 (20 mM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra showing peak responses before (solid line) and after (dashed line) application of SYM2206. (iv) Bar
graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. (B) Effect of the non-competitive NMDA receptor antagonist MK-801 (20 mM) on (i) theta and (ii) gamma oscillations.
(iii) Representative power spectra demonstrating peak responses before (solid line) and after (dashed line) application of 20 mM MK-801. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars)
oscillations normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
N
.W
.Johnson
et
al./
N
europharm
acology
119
(2017)
141
e
156
150
Fig. 8. Blocking group I metabotropic glutamate receptors increases the power of theta and gamma oscillations in layer V of M1.
(A) Effect of the mGluR1 antagonist CPCCOEt (20 mM) on (i) theta and (ii) gamma oscillations. (iii) Representative power spectra showing peak responses before (solid line) and after
(dashed line) application of CPCCOEt. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. (B) Effect of
mGluR5 antagonist MTEP (100 nM) on (i) theta and (ii) gamma oscillations (iii) Representative power spectra demonstrating peak responses before (solid line) and after (dashed
line) application of MTEP. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. *p < 0.05 **p < 0.01,
***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 9. Block of gap junctions and muscarinic acetylcholine receptors decreases power of theta and gamma oscillations.
(A) Effects of the gap junction blocker, carbenoxalone, (200 mM) on (i) theta and (ii) gamma oscillations. (iii) Associated power spectra demonstrating peak responses before (solid line) and after (dashed line) application of carbe-
noxolone. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations normalised to control. (B) Effects of the mACh receptor blocker atropine (5 mM) on (i) theta and (ii) gamma oscillations.
(iii) Associated power spectra demonstrating peak responses before (solid line) and after (dashed line) application of atropine. (iv) Bar graphs showing peak oscillatory power of theta (grey bars) and gamma (red bars) oscillations
normalised to control. *p < 0.05 **p < 0.01, ***p < 0.001. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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N.W. Johnson et al. / Neuropharmacology 119 (2017) 141e156 153generated by discrete mechanisms, responding differentially to a
range of pharmacological interventions at the major CNS excitatory
and inhibitory receptors. Consistent with previous reports in cortex
(e.g. Roopun et al., 2006), gamma activity was exquisitely sensitive
to blockade of fast synaptic inhibition, but was also sensitive to gap
junction block. Theta activity was much less sensitive to modula-
tion of fast synaptic inhibition and excitation, suggesting a greater
reliance on non-synaptic mechanisms. Further study of dual theta-
gamma activity in the in vitro slice preparation has the potential to
allow greater mechanistic understanding of how phase-amplitude
coupling is mediated at the cellular and local network level, and
how it is modulated by pharmacological manipulation.
4.1. KA and CCh generate simultaneous theta and gamma
oscillations in layer V M1 in vitro
Co-application of KA and CCh has been used to generate gamma
oscillations in vitro in hippocampus (Fisahn et al., 1998), somato-
sensory cortex (Buhl et al., 1998; Roopun et al., 2006) and ento-
rhinal cortex (Cunningham et al., 2003). We have previously used
higher concentrations of KA and CCh (400 nM and 50 mM respec-
tively) to generate beta oscillations in M1 (Yamawaki et al., 2008).
However, in the present studies we have found that lower con-
centrations (100e150 nM kA and 5e10 mM CCh), are capable of
producing multiple rhythms.
In relation to the novel observation of dual rhythms, we suspect
that these differences are due to the improved viability of our M1
slice, and probably reﬂect better preservation of the GABA in-
terneurons required for rhythmogenesis. As detailed in the
Methods section above, we have utilised a number of ‘neuro-
protectant’ agents during slice preparation, namely NAC, amino-
guanidine, taurine, ethyl pyruvate and ascorbate, and these agents
provided a step-change in slice viability and successful production
of neuronal network oscillations in deep M1. When we performed
immunocytochemistry for common interneuronal proteins such as
parvalbumin (PV), calbindin and somatostatin, we did not observe a
notable change in preservation of inhibitory cell somata compared
to standard aCSF (data not shown), but we did see evidence of
better dendritic preservation, though this is hard to quantify.
NAC has been shown to have neuroprotectant actions, restoring
mitochondrial function in traumatic brain injury (Xiong et al., 1999)
and increasing the pool of glutathione, a reactive oxygen species
(ROS) scavenger (Chen et al., 2008; Ferrari et al., 1995). Amino-
guanidine is a ROS scavenger associated with preventing apoptosis
after ischemia (Dawson et al., 1993; Hunot et al., 1996; Sun et al.,
2010). Taurine, a modulator of cytosolic and intra-mitochondrial
calcium concentrations, can be employed to prevent mitochon-
drial death, and thus cell death, during traumatic events (Ellren and
Lehmann, 1989). Similarly, cell volume regulation is a vital process
(Inoue et al., 2005) and is regulated in part by taurine (Beetsch and
Olson, 1998). Ascorbic acid, an important antioxidant and neuro-
modulator is found at its highest concentration in the brain (Rice,
2000). It is found in CSF and extracellular ﬂuid and is taken up by
neurones where it is found at its highest concentration at 10 mM.
Providing ascorbic acid in the modiﬁed aCSF means it can directly
scavenge ROS and can be hetero-exchanged with glutamate,
increasing levels in the extracellular ﬂuid to minimise excitotox-
icity. The standard aCSF solution used pyruvate in its salt form
(sodium pyruvate). However, sodium pyruvate has been shown to
be unstable and to dimerize rapidly into pyruvate hydrate and
subsequently more slowly into parapyruvate, a compound that
actually inhibits energy generation in neurones in vitro (Moyer
et al., 2011; Zeng et al., 2007). Ethyl pyruvate, the ester form of
pyruvic acid was thus used instead to help promote ATP generation.
As ethyl pyruvate is lipophilic, it may penetrate into cells, where itcan be hydrolysed by intracellular esterases to release pyruvate
(Sims et al., 2001).
Taken together, these neuroprotectants combined in a modiﬁed
aCSF solution have increased the preservation of neurons inM1 and
also helped to increase number of slices that display neuronal
network activity and show a deﬁnitive enhancement in slice
viability.
4.2. Dependence of theta-gamma activity on excitatory and
inhibitory synaptic transmission
Whilst their dependence on both KA and CCh may imply that
the method of generation for both gamma and theta oscillations in
M1 is similar, pharmacological characterisation reveals differences.
Hence, gamma oscillatory power in M1 was signiﬁcantly reduced
by the GABAA antagonists gabazine and picrotoxin and the AMPA
receptor blocker SYM2206 indicating dependence on recurrent
excitatory and inhibitory synaptic transmission. By contrast theta
oscillatory power was increased by block of either GABAA and
AMPA receptors, consistent with a non-synaptically coupled
network of oscillators in which synaptic blockade augments a non-
synaptically generated rhythm (e.g. the beta 2 rhythm in somato-
sensory cortex in vitro as shown by Roopun et al., 2006). Activation
of the benzodiazepine site of the GABAA receptor with diazepam
and zolpidem application resulted in increases in power of both
theta and gamma oscillations, although the effect on theta rhythm
is only observed at the highest concentrations of either drug. These
data are consistent with the known synaptic inhibitory compo-
nents of gamma oscillations, and suggest that the theta network
may have a synaptic component as well as the previously discussed
non-synaptic element and this may explain the shift in peak theta
frequency seen between addition of CCh and subsequent addition
of KA. The effects of benzodiazepine site agonists are suggestive of
an increase in oscillatory power following recruitment and syn-
chronous activation of pyramidal neurons, and may be related to
the enhanced beta activity or ‘beta buzz’ seen in vivo (Glaze, 1990).
Recent evidence suggests that a sustained inhibitory membrane
conductance (Itonic), arising from spill over of GABA, and mediated
by high afﬁnity extrasynaptic GABAA receptors (Bright et al., 2007;
Farrant and Nusser, 2005) also plays a fundamental role in shaping
network excitability (Mann andMody, 2010; Semyanov et al., 2004)
and this current is also present in M1, playing a role in beta oscil-
latory activity (Prokic et al., 2015).
Blockade of NMDA receptors with NMDAR antagonists signiﬁ-
cantly increased power in both the theta and gamma band in M1,
consistent with other reports of such NMDAR antagonist effects in
the literature (Hakami et al., 2009; McNally et al., 2011; Pinault,
2008). It has been reported that GABA interneurons in hippocam-
pal CA1 are highly sensitive to NMDAR antagonism (Grunze et al.,
1996), and selective genetic ablation of NMDAR on parvalbumin
positive (PVþ) interneurons has been shown to augment gamma
activity in the same region (Korotkova et al., 2010), with disinhi-
bition of GABA interneurons being suggested as a mechanism for
augmented excitability in pyramidal neurons, leading to increased
oscillatory power. In the same study, Korotkova et al. (2010)
showed selective interneuronal NMDAR ablation reduced theta
power in CA1, an effect not seen in M1. This may reﬂect different
local circuit organisation between hippocampus and neocortex, or
simply be due to the acute versus chronic effects of ablation as
compared to pharmacological intervention. Interestingly, the
competitive antagonists, CPP and 2-AP5 did not affect theta power
in our experiments, suggesting that NMDAR on GABA interneurons
responsible for theta generation are not blocked at the concentra-
tions used. The augmentation of theta power in hippocampus by
NMDA antagonists contrasts with previous reports of theta power
N.W. Johnson et al. / Neuropharmacology 119 (2017) 141e156154reduction in CA1 (Gillies et al., 2002).
4.3. Gap junctions are required for both theta and gamma
oscillations
Networks of inhibitory interneurons are known to be connected
together by gap junctions, which allow them to provide large
synchronous IPSPs to local excitatory cells involved in oscillations
(Deans et al., 2001; Galarreta and Hestrin,1999; Gibson et al., 1999).
Pharmacological blockade of gap junction function with carbe-
noxolone, has been shown to abolish ultrafast oscillations (80e200
Hz, Draguhn et al., 1998) and gamma/beta oscillation in vitro
(Cunningham et al., 2003; Deans et al., 2001; Roopun et al., 2006;
Traub et al., 2000). Consistent with these observations, applica-
tion of carbenoxolone, a gap junction channel blocker, here
decreased and abolished theta and gamma oscillations respectively,
conﬁrming the essential nature of the inhibitory input provided by
the interneuronal network.
4.4. mGluR mediated modulation of theta and gamma oscillations
Activation of mGluRs has in the past been shown to elicit
gamma oscillations in hippocampus and neocortical slices via
networks of interneurons (Whittington et al., 1995), reﬂecting the
increase in network excitability seen in response to group I mGluR
activation. Herewe show that the addition of antagonists of group I
mGluRs results in increased theta and gamma oscillatory power.
Previous studies have reported that activation of group I mGluRs
decreased synaptic inhibition (Desai and Conn, 1991; Varma et al.,
2001) and it seems likely that blockade of mGluRs may result in
increased synaptic inhibition, either through reduction in consti-
tutive activity at the receptor or through reduction of glutamate
driven activation of mGluRs in the KA/CCh activated network. In
such a scenario, increased action-potential dependent GABA
releasemay lead to increased oscillatory power in the samemanner
that positive modulation of GABAA receptors with benzodiazepines
or barbiturates are known to do.
4.5. Theta-gamma cross-frequency coupling in M1
CFC (which includes PAC as well as many other forms of
coupling) aids inter-network computational processing and
communication and has been identiﬁed in behaving rats (Bragin
et al., 1995; Buzsaki and Chrobak, 1995; Quilichini et al., 2010),
monkeys (Lakatos et al., 2005) and in man (Mormann et al., 2005).
CFC manifests between multiple brain regions in response to sen-
sory inputs and cognitive or motor tasks and, as such, CFC is
believed to be the primary mechanism by which brain areas and
neuronal networks spatially and temporally co-ordinate activity
(Gray et al., 1989; Jensen and Colgin, 2007). Igarashi et al. (2013)
demonstrated the importance of theta and gamma oscillatory CFC
in the sensorimotor area in vivo, suggesting that coupling between
different ranges of gamma oscillations (high and low) was a dy-
namic systemwhich could be attributed to differentmovement and
behavioural states. To date, reports of CFC have been based on re-
cordings made in vivo (Bragin et al., 1995; Chrobak and Buzsaki,
1998; Csicsvari et al., 2003; Mormann et al., 2005; Quilichini
et al., 2010; Tort et al., 2008), and the current report is, to our
knowledge, the ﬁrst demonstration of CFC in an in vitro preparation
of primary motor cortex.
Many studies have reported the importance of interneurons in
generating synchronised IPSPs/IPSCs that contribute to the gener-
ation of gamma oscillations (e.g. Traub et al., 1996; Whittington
et al., 1995). Similarly, mechanistic investigations in mouse hippo-
campal area CA1 in vivo, have shown speciﬁcally that coupling (andnot simply amplitude) of theta-gamma oscillations requires intact
GABA inhibition onto PV þ interneurons (Wulff et al., 2009). The
coupled oscillatory activity we have reported here suggests that the
relevant inhibitory networks in the M1 slice remain intact and that
this preparation may prove useful for further mechanistic study of
CFC in vitro.
5. Conclusions
These data show simultaneous theta and gamma oscillatory
activity in layer V of M1 shows cross-frequency coupling and that
the coupled rhythms are generated by different mechanisms.
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